Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply

Lancet. 2021 Jul 24;398(10297):302. doi: 10.1016/S0140-6736(21)00876-X.

Authors

Paul Baas¹, Arnaud Scherpereel², Anna K Nowak³, Abderrahim Oukessou⁴, Gerard Zalcman⁵

Affiliations

¹ Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands. Electronic address: [email protected].
² Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, Lille, France.
³ Medical School, University of Western Australia, Perth, WA, Australia.
⁴ Bristol Myers Squibb, Princeton, NJ, USA.
⁵ Bichat-Claude Bernard University Hospital, Université de Paris, Paris, France.

PMID: 34303436
DOI: 10.1016/S0140-6736(21)00876-X

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Mesothelioma* / drug therapy
Mesothelioma, Malignant*
Pleural Neoplasms* / drug therapy